Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction

Area of Science:

• Immunometabolism
• Mitochondrial Biology
• Obesity Pathophysiology

Background:

• Obesity promotes low-grade inflammation and mitochondrial dysfunction, key drivers of metabolic disorders.
• Hypertrophied adipose tissue releases pro-inflammatory cytokines and free fatty acids, leading to insulin resistance and lipid deposition.
• Mitochondrial dysfunction, including ROS production and DNA damage, activates inflammatory pathways like the NLRP3 inflammasome, creating a detrimental feedback loop.

Purpose of the Study:

• To elucidate the interconnected roles of inflammation and mitochondrial dysfunction in obesity-related metabolic diseases.
• To highlight the shared pathophysiological features of type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD).
• To explore potential therapeutic strategies targeting inflammation and mitochondrial health.

Main Methods:

• Review of existing literature on obesity, inflammation, mitochondrial function, T2DM, and MASLD.
• Analysis of the molecular mechanisms linking adipose tissue dysfunction to systemic metabolic derangements.
• Examination of the role of oxidative stress and inflammasome activation in disease progression.

Main Results:

• Obesity-induced inflammation and mitochondrial dysfunction disrupt energy balance, insulin signaling, and β-cell function.
• Shared features in T2DM and MASLD include oxidative stress, impaired mitochondrial quality control, and dysregulated immunometabolism.
• A positive feedback loop exists between mitochondrial dysfunction and inflammatory pathways, exacerbating metabolic stress.

Conclusions:

• Inflammation and mitochondrial dysfunction are central to the pathogenesis of obesity-related T2DM and MASLD.
• Therapeutic interventions focusing on reducing inflammation and restoring mitochondrial function show promise.
• Lifestyle modifications and targeted therapies offer potential strategies to mitigate disease progression.